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2008-2009 Influenza Season 
Week 18 ending May 9, 2009 
All data are preliminary and may change as more reports are received. 
(Due to the response to the novel influenza A (H1N1) investigation, surveillance regions were 
changed from Census Divisions to Department of Health and Human Services (HHS) Regions.) 
 
Synopsis:  During week 18 (May 3 - 9, 2009), influenza activity remained at approximately the 
same level as last week in the United States, indicating that there are higher levels of influenza-like 
illness than is normal for this time of year.   
o One thousand four hundred fifty-four (11.9%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive 
for influenza. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o Three influenza-associated pediatric deaths were reported. 
o The proportion of outpatient visits for influenza-like illness (ILI) was above the national 
baseline.  Three of the ten surveillance regions reported ILI above their region-specific 
baselines. 
o Eight states reported geographically widespread influenza activity, 14 states reported 
regional activity, the District of Columbia and 15 states reported local influenza activity; and 
13 states reported sporadic influenza activity. 
 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) Novel A H1N1
A  
(could 
not be 
sub-
typed)¥ 
A 
 (Un-
sub-
typed) 
B  Pediatric Deaths 
Nation Elevated 11.9% 22 of 51  7,114 1,351 1,036 425 11,046 9,679 59 
Region I Normal 9.8% 4 of 6 524 130 132 13 1,079 794 1 
Region II Normal 14.5% 2 of 2 265 100 101 4 1,035 704 8 
Region III Normal 11.9% 3 of 6 1,144 132 71 40 610 1,330 9 
Region IV Elevated 9.0% 4 of 8 749 61 34 24 1,615 1,120 6 
Region V Normal 14.1% 0 of 6 1,561 128 487 170 467 1,249 9 
Region VI Normal 4.7% 2 of 5 713 83 34 4 3,884 2,414 12 
Region VII Normal 23.7% 0 of 4 483 44 74 107 443 518 0 
Region VIII Normal 10.5% 2 of 6 461 191 36 47 1,358 470 5 
Region IX Elevated 11.6% 4 of 4 890 263 12 12 257 436 8 
Region X Elevated 25.0% 1 of 4 324 219 55 4 298 644 1 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, 
FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, 
SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states and the District of Columbia 
¥ >99% of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further testing 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.  
 
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  On April 15 and 17, 2009, CDC confirmed that two cases of febrile respiratory illness 
occurring in children who reside in adjacent counties in southern California were caused by 
infection with a novel influenza A (H1N1) virus. As of May 15, 2009, 4,714 confirmed infections with 
novel influenza A (H1N1) virus have been identified by CDC and state and local public health 
departments.  Reporting of novel influenza A (H1N1) viruses by U.S. WHO collaborating 
laboratories began during week 17.  The results of tests performed during the current week are 
summarized in the table below. 
 
 Week 18 
No. of specimens tested 12,202 
No. of positive specimens (%) 1,454 (11.9%) 
Positive specimens by type/subtype  
Influenza A 1,286 (88.4%) 
        A (H1)         178 (13.8%) 
        A (H3)         150 (11.7%) 
        A (unsubtyped)         314 (24.4%) 
        A (could not be subtyped)                    203 (15.8%) 
        A (novel influenza H1N1)                    441 (34.3%) 
Influenza B 168 (11.6%) 
 
During week 18, seasonal influenza A (H1), A (H3), and B viruses continue to co-circulate with 
novel influenza A (H1N1).  About half of all influenza viruses being detected are novel H1N1 
viruses. 
 
The number of specimens tested by WHO and NREVSS collaborating laboratories during week 18 
increased in response to the ongoing novel influenza A (H1N1) investigations.  The increase in the 
percentage of specimens testing positive for influenza also may be due in part to changes in testing 
practices by healthcare providers, triaging of specimens by public health laboratories, an increase 
in the number of specimens collected from outbreaks, and other factors. 
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Antigenic Characterization:  CDC has antigenically characterized 1,317 seasonal human 
influenza viruses [827 influenza A (H1), 140 influenza A (H3) and 350 influenza B viruses] collected 
by U.S. laboratories since October 1, 2008.   
All 827 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  All 140 influenza A (H3N2) viruses are related 
to the A (H3N2) vaccine component (A/Brisbane/10/2007).      
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Fifty-six influenza B viruses tested belong to the 
B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 294 
viruses belong to the B/Victoria lineage and are not related to the vaccine strain.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference 
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ferret antisera and results may not correlate with clinical protection against circulating viruses 
provided by influenza vaccination. 
Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of novel influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 865 seasonal influenza A (H1N1), 134 influenza A 
(H3N2), and 424 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Eight hundred seventy-six seasonal influenza A (H1N1) and 
145 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine 
and rimantadine).  One hundred one novel influenza A (H1N1) viruses have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  Ninety-six novel influenza A 
(H1N1) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine).  
The results of antiviral resistance testing performed on these viruses are summarized in the table 
below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 865 860 (99.4%) 0 (0) 876 4 (0.5%) 
Influenza A (H3N2) 134 0 (0) 0 (0) 145 145 (100%) 
Influenza B 424 0 (0) 0 (0) N/A* N/A* 
Novel Influenza A  
(H1N1) 101 0 (0) 0 (0) 96 96 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with 
confirmed, probable or suspected cases of novel influenza A (H1N1) virus infection who are 
hospitalized or who are at higher risk for seasonal influenza complications.  The novel influenza A 
(H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and 
oseltamivir.  It is resistant to the adamantane antiviral medications, amantadine and 
rimantadine. Additional information on antiviral recommendations for treatment and 
chemoprophylaxis of novel influenza A (H1N1) infection is available at 
http://www.cdc.gov/h1n1flu/recommendations.htm 
 
In areas that continue to have seasonal influenza activity, especially those with circulation of 
oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use 
either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide 
adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human 
influenza A (H1N1) virus infection. 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 18, 7.2% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is 
below to the epidemic threshold of 7.4% for week 18. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending 5/9/2009 
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Influenza-Associated Pediatric Mortality:  Three influenza-associated pediatric deaths were 
reported to CDC during week 18 (Arizona, California, and Texas); one was due to influenza A virus 
(rapid test positive) and two were due to influenza B virus infections.  The deaths reported this week 
occurred between April 5 and May 2, 2009.  Since September 28, 2008, CDC has received 59 
reports of influenza-associated pediatric deaths that occurred during the current season.   
 
Of the 30 children who had specimens collected for bacterial culture from normally sterile sites, 13 
(43.3%) were positive; Staphylococcus aureus was identified in eight (61.5%) of the 13 children.  
Three of the S. aureus isolates were sensitive to methicillin and five were methicillin resistant.   
Twelve of the 13 children with bacterial coinfections were five years of age or older and 10 (76.9%) 
of the 13 children were 12 years of age or older.  An increase in the number of influenza-associated 
pediatric deaths with bacterial coinfections was first recognized during the 2006-07 influenza 
season.  In January 2008, interim testing and reporting recommendations were released regarding 
influenza and bacterial coinfections in children and are available at 
(http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268). 
 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2005-06 season to present 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).  These two systems 
provide updates of surveillance data every two weeks. 
 
During October 12, 2008 to May 2, 2009, the preliminary laboratory-confirmed influenza-associated 
hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. Because of case 
identification methods utilized in this study, there is a delay from the date of hospitalization to the 
date of report.  
 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During October 1, 2008 – May 9, 2009, preliminary laboratory-confirmed influenza-associated 
hospitalization rates reported by the EIP for children aged 0-4 years and 5-17 years were 3.6 per 
10,000 and 0.7 per 10,000, respectively.  For adults aged 18-49 years, 50-64 years, and ≥ 65 
years, the rates were 0.4 per 10,000, 0.5 per 10,000, and 1.4 per 10,000, respectively. 
 
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates,  
2008-09 and Previous Three Seasons 
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Outpatient Illness Surveillance: Nationwide during week 18, 2.6% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is above the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of visits for ILI ranged from 1.1% to 6.2%. Three of the ten 
surveillance regions reported an ILI percentage above their region specific baselines. 
 
 
 
 
 
 
 
 
 
 
 
 
2008-2009 Influenza Season – Week 18, ending May 9, 2009           
 
 10
 
 
R eg io n I -  C T,  M E, M A, NH, RI , VT
0
1
2
3
4
5
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
is
its
 fo
r 
R eg io n VI  -  AR , L A, NM , OK,  TX
0
2
4
6
8
10
12
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
is
its
 fo
r 
Re gio n  II  -  NJ,  NY
0
2
4
6
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
is
it
s f
or
 I
Re gio n III  -  DE , D C, M D,  PA, VA, W V
0
2
4
6
8
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
isi
ts 
fo
r 
Re gio n  IV - A L, FL,  G A, K Y, M S,  NC , SC, T N
0
2
4
6
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
is
it
s f
or
 
R eg ion  V - IL , I N, M I, M N, OH,  W I
0
2
4
6
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
is
it
s f
or
 
Re gio n VII - IA, KS, M O,  NE
0
2
4
6
8
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f 
Vis
it
s f
or
 I
Re g ion  VII I -  C O,  M T , ND,  SD,  UT ,  W Y
0
1
2
3
4
5
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f 
V
isi
ts 
fo
r 
Re gio n  IX - A Z,  C A, H I, NV
0
2
4
6
8
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f 
Vis
it
s f
or
 
R eg ion  X - AK, ID,  O R, W A
0
2
4
6
8
10
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f 
Vis
it
s f
or
 I
NO TE: Sca les  dif fer  b et wee n re gio ns
NO TE: The re  wa s n o we ek 53  d uri ng  th e 2 00 6- 0 7 a nd  2 00 7- 08  s eas on s, th er efo re  th e we ek 53  d ata  p oin t f or th os e s eas on s is  an  a ver ag e  of  we eks  
5 2 a nd  1 .
2006-07 2007-08 2008-09 Baseli ne
2008-2009 Influenza Season – Week 18, ending May 9, 2009           
 
 11
 
Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 18, the following influenza activity was reported: 
? Widespread influenza activity was reported by eight states (Arizona, California, Delaware, 
Georgia, New Jersey, New Mexico, Texas, and Virginia). 
? Regional influenza activity was reported by 14 states (Alabama, Alaska, Colorado, 
Connecticut, Florida, Hawaii, Maine, Maryland, Massachusetts, Nevada, New Hampshire, 
New York, Tennessee, and Utah). 
? Local influenza activity was reported by the District of Columbia and 15 states (Idaho, 
Illinois, Iowa, Kansas, Michigan, Montana, North Carolina, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, South Carolina, Washington, Wisconsin, and Wyoming). 
? Sporadic activity was reported by 13 states (Arkansas, Indiana, Kentucky, Louisiana, 
Minnesota, Mississippi, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Vermont, 
and West Virginia). 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: May 15, 2009. 
